Piper Sandler Keeps Their Buy Rating on Sutro Biopharma (STRO)

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Sutro Biopharma (STRO – Research Report), with a price target of $11.00. The company’s shares closed yesterday at $5.09.

Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Moderna, and Arrowhead Pharmaceuticals. According to TipRanks, Tenthoff has an average return of 3.5% and a 37.95% success rate on recommended stocks.

Sutro Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $12.00, implying a 135.76% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $17.00 price target.

Based on Sutro Biopharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $113.72 million and a net profit of $31.07 million. In comparison, last year the company earned a revenue of $8.63 million and had a GAAP net loss of $34.59 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sutro Biopharma (STRO) Company Description:

Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.